The changing face of p53 in head and neck cancer

International Journal of Oral and Maxillofacial Surgery

Volumn 36, Issue 12, 2007, Pages 1123-1138

  Partridge, M ^a   Costea, D E ^b   Huang, X ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; FLUOROURACIL; PACLITAXEL; PROTEIN P53; PROTEIN P63; PROTEIN P73;

ANEUPLOIDY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELLULAR DISTRIBUTION; DNA DAMAGE; DRUG MECHANISM; GENE MUTATION; GENE STRUCTURE; GENE TARGETING; GENE THERAPY; GENETIC DATABASE; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; MOUTH MUCOSA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; DNA DAMAGE; DNA-BINDING PROTEINS; FLUOROURACIL; GENE THERAPY; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; NUCLEAR PROTEINS; PEPTIDE TERMINATION FACTORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 36248986769     PISSN: 09015027     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijom.2007.06.006     Document Type: Review

References (103)

1. Abbas T., White D., Hui L., Yoshida D.A., and Bargonetti J. Inhibition of human p53 basal transcription by down-regulation of protein kinase Cdelta. J Biol Chem 279 (2004) 9970-9977
2. Ahomadegbe J.C., Barrois M., Fogel S., Le Bihan M.L., Douc-Rasy S., Duvillard P., Armand J.P., and Riou G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10 (1995) 1217-1227
3. Balz V., Scheckenbach K., Gotte K., Bockmuhl U., Petersen I., and Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63 (2003) 1188-1191
4. Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigante G., Yulug I., Merlano M., Numico G., Comino A., Attard M., Reelfs O., Gusterson B., Bell A.K., Heath V., Tavassoli M., Farrell P.J., Smith P., Lu X., and Crook T. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3 (2003) 387-402
5. Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., Hsieh J.K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L., Kuwabara P.E., and Lu X. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33 (2003) 162-167
6. Bradford C.R., Zhu S., Ogawa H., Ogawa T., Ubell M., Narayan A., Johnson G., Wolf G.T., Fisher S.G., and Carey T.E. p53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25 (2003) 654-661
7. Brennan J.A., Mao L., Hruban R.H., Boyle J.O., Eby Y.J., Koch W.M., Goodman S.N., and Sidransky D. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332 (1995) 429-435
8. Bosch F.X., Ritter D., Enders C., Flechtenmacher C., Abel U., Dietz A., Hergenhahn M., and Weidauer H. Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer 111 (2004) 530-538
9. Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., Correo R., Eby Y.J., Ruppert J.M., and Sidransky D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53 (1993) 4477-4480
10. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., and Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8 (2002) 282-288
11. Cabelguenne A., Blons H., de Waziers I., Carnot F., Houllier A.M., Soussi T., Brasnu D., Beaune P., Laccourreye O., and Laurent-Puig P. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18 (2000) 1465-1473
12. Cai Y.C., Yang G.Y., Nie Y., Wang L.D., Zhao X., Song Y.L., Seril D.N., Liao J., Xing E.P., and Yang C.S. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis 21 (2000) 683-689
13. Choi H.R., Batsakis J.G., Zhan F., Sturgis E., Luna M.A., and El-Naggar A.K. Differential expression of p53 gene family members p63 and p7P3 in head and neck squamous tumorigenesis. Hum Pathol 33 (2002) 158-164
14. Clayman G.L., El-Naggar A.K., Lippman S.M., Henderson Y.C., Frederick M., Merritt J.A., Zumstein L.A., Timmons T.M., Liu T.J., Ginsberg L., Roth J.A., Hong W.K., Bruso P., and Goepfert H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16 (1998) 2221-2232
15. Clayman G.L., Frank D.K., Bruso P.A., and Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 5 (1999) 1715-1722
16. Cutilli T., Papola F., Di Emidio P., Leocata P., and Corbacelli A. p53 mutations and chemoresistance in oromaxillofacial squamous-cell carcinomas. The results of a molecular genetics study of p53 in metastatic tumors and an evaluation of the response to neoadjuvant chemotherapeutic treatment. Minerva Stomatol 47 (1998) 1-9
17. Dai M., Clifford G.M., le Calvez F., Castellsage X., Snijders P.J., Pawlita M., Herrero R., Hainaut P., Franceschi S., and IARC Multicenter Oral Cancer Study Group. Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res 64 (2004) 468-471
18. Denissenko M.F., Pao A., Tang M., and Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274 (1996) 430-432
19. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., Appella E., and Soddu S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4 (2002) 11-19
20. Dumont P.J., Leu I.-J., Pietra III A.C.D., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
21. Duensing A., and Duensing S. Guilt by association? p53 and the development of aneuploidy in cancer. Biochem Biophys Res Commun 331 (2005) 694-700
22. El-Naggar A.K., Lai S., Luna M.A., Zhou X.D., Weber R.S., Goepfert H., and Batsakis J.G. Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. Int J Cancer 64 (1995) 196-201
23. Eriksen J.G., Buffa F.M., Alsner J., Steiniche T., Bentzen S.M., and Overgaard J. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiother Oncol 72 (2004) 275-282
24. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., and Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416 (2002) 560-564
25. Fomenkov A., Huang Y.P., Topaloglu O., Brechman A., Osada M., Fomenkova T., Yuriditsky E., Trink B., Sidransky D., and Ratovitski E. p63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome. J Biol Chem 278 (2003) 23906-23914
26. Fouret P., Temam S., Charlotte F., and Lacau-St-Guily J. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Br J Cancer 87 (2002) 1390-1395
27. Frederick M.J., Holton P.R., Hudson M., Wang M., and Clayman G.L. Expression of apoptosis-related genes in human head and neck squamous cell carcinomas undergoing p53-mediated programmed cell death. Clin Cancer Res 5 (1999) 361-369
28. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., Zahurak M.L., Daniel R.W., Viglione M., Symer D.E., Shah K.V., and Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 (2000) 709-720
29. Greenblatt M.S., Bennett W.P., Hollstein M., and Haris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54 (1994) 4855-4878
30. Gudkov A.V., and Komarova E.A. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3 (2003) 117-129
31. Hafkamp H.C., Speel E.J., Haesevoets A., Bot F.J., Dinjens W.N., Ramaekers F.C., Hopman A.H., and Manni J.J. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 107 (2003) 394-400
32. Hall P.A., and Lane D.P. p53 in tumour pathology: can we trust immunohistochemistry? - Revisited!. J Pathol 172 (1994) 1-4
33. Harden S.V., Thomas D.C., Benoit N., Minhas K., Westra W.H., Califano J.A., Koch W., and Sidransky D. Real-time gap ligase chain reaction: a rapid semi-quantitative assay for detecting p53 mutation at low levels in surgical margins and lymph nodes from resected lung and head and neck tumors. Clin Cancer Res 10 (2004) 2379-2385
34. Herrero R. Chapter 7: Human papillomavirus and cancer of the upper aerodigestive tract. J Natl Cancer Inst Monogr 31 (2003) 47-51
35. Hibi K., Trink B., Patturajan M., Westra W.H., Caballero O.L., Hill D.E., Ratovitski E.A., Jen J., and Sidransky D. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 97 (2000) 5462-5467
36. Honeycutt K.A., Koster M.I., and Roop D.R. Genes involved in stem cell fate decisions and commitment to differentiation play a role in skin disease. J Investig Dermatol Symp Proc 9 (2004) 261-268
37. Hong Y., Miao X., Zhang X., Ding F., Luo A., Guo Y., Tan W., Liu Z., and Lin D. The role of p53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65 (2005) 9582-9587
38. Hu H., Xia S.H., Li A.D., Xu X., Cai Y., Han Y.L., Wei F., Chen B.S., Huang X.P., Han Y.S., Zhang J.W., Zhang X., Wu M., and Wang M.R. Elevated expression of p63 protein in human esophageal squamous cell carcinomas. Int J Cancer 102 (2002) 580-583
39. Jamieson E.R., and Lippard S.J. Structure and processing of cisplatin-DNA adducts. Chem Rev 98 (1999) 2467-2498
40. Jeffrey P.D., Gorina S., and Pavletich N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267 (1995) 1498-1502
41. Jost C.A., Marin M.C., and Kaelin Jr. W.G. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389 (1997) 191-194
42. Kaelin W.G. The p53 gene family. Oncogene 18 (1999) 7701-7715
43. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F., and Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
44. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., Gore M., Ironside J., MacDougall R.H., Heise C., Randlev B., Gillenwater A.M., Bruso P., Kaye S.B., Hong W.K., and Kirn D.H. A controlled trial of intratumoural ONYX-015 a selectively-replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6 (2000) 879-885
45. Koch W.M., Lango M., Sewell D., Zahurak M., and Sidransky D. Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope 109 (1999) 1544-1551
46. Komarova E.A., and Gudkov A.V. Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors. Biochem Pharmacol 62 (2001) 657-667
47. Koster M., Huntzinger K.A., and Roop D.R. Epidermal differentiation: transgenic/knockout mouse models reveal genes involved in stem cell fate decisions and commitment to differentiation. J Invest Dermatol Symp Proc 7 (2002) 41-45
48. Kress S., Sutter C., Strickland P.T., Mukhtar H., Schweizer J., and Schwarz M. Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. Cancer Res 52 (1992) 6400-6413
49. Kropveld A., Rozemuller E.H., Leppers F.G., Scheidel K.C., de Weger R.A., Koole R., Hordijk G.J., Slootweg P.J., and Tilanus M.G. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab Invest 79 (1999) 347-353
50. Lane D.P. Cancer. p53, guardian of the genome. Nature 358 (1992) 15-16
51. Larsen A.K., Escargueil A.E., and Skladanowski A. From DNA damage to G2 arrest: the many roles of topoisomerase II. Prog Cell Cycle Res 5 (2003) 295-300
52. Lee S.K., Kim S.B., Kim J.S., Moon C.H., Han M.S., Lee B.J., Chung D.K., Min Y.J., Park J.H., Choi D.H., Cho H.R., Park S.K., and Park J.W. Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines. Int J Cancer 117 (2005) 32-40
53. Leng K., Schlien S., and Bosch F.X. Refined characterization of head and neck squamous cell carcinomas expressing a seemingly wild-type p53 protein. J Oral Pathol Med 35 (2006) 19-24
54. Mantovani F., and Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20 (2001) 7874-7887
55. Marin M.C., Jost C.A., Brooks L.A., Irwin M.S., O'Nions J., Tidy J.A., James N., McGregor J.M., Harwood C.A., Yulug I.G., Vousden K.H., Allday M.J., Gusterson B., Ikawa S., Hinds P.W., Crook T., and Kaelin W.G. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25 (2000) 47-54
56. Martinez L.A., Naguibneva I., Lehrmann H., Vervisch A., Tchénio T., Lozano G., and Harel-Bellan A. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 99 (2002) 14849-14854
57. McCluggage W.G., Connolly L.E., McGregor G., Hyland P.L., and Hall P.A. A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int J Gynecol Pathol 24 (2005) 307-312
58. Medema R.H., Klompmaker R., Smits V.A., and Rijksen G. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 16 (1998) 431-441
59. Melino G., Bernassola F., Ranalli M., Yee K., Zong W.X., Corazzari M., Knight R.A., Green D.R., Thompson C., and Vousden K.H. p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279 (2004) 8076-8083
60. Melino G. p73, the 'assistant' guardian of the genome?. Ann N Y Acad Sci 1010 (2003) 9-15
61. Moll U.M., and Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2 (2004) 371-386
62. Morley S., MacDonald G., Kirn D., Kaye S., Brown R., and Soutar D. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res 10 (2004) 4357-4362
63. Nemunaitis J., Khuri F., Ganly I., Arseneau J., Posner M., Vokes E., Kuhn J., McCarty T., Landers S., Blackburn A., Romel L., Randlev B., Kaye S., and Kirn D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19 (2001) 289-298
64. Nemunaitis J., Swisher S.G., Timmons T., Connors D., Mack M., Doerksen L., Weill D., Wait J., Lawrence D.D., Kemp B.L., Fossella F., Glisson B.S., Hong W.K., Khuri F.R., Kurie J.M., Lee J.J., Lee J.S., Nguyen D.M., Nesbitt J.C., Perez-Soler R., Pisters K.M., Putnam J.B., Richli W.R., Shin D.M., Walsh G.L., Merritt J., and Roth J. Adenovirus -mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18 (2000) 609-622
65. Nenutil R., Smardova J., Pavlova S., Hanzelkova Z., Muller P., Fabian P., Hrstka R., Janotova P., Radina M., Lane D.P., Coates P.J., and Vojtesek B. Discriminating functional and non-functional p53 in human tumours by immunohistochemistry. J Pathol 207 (2005) 251-259
66. Nylander K., Nilsson P., Mehle C., and Roos G. p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Br J Cancer 71 (1995) 826-830
67. Oakley R., Phillips E., Hooper R., Wilson D., and Partridge M. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer. Clin Cancer Res 8 (2002) 1984-1994
68. O'Shea C.C., Johnson L., Bagus B., Choi S., Nicholas C., Shen A., Boyle L., Pandey K., Soria C., Kunich J., Shen Y., Habets G., Ginzinger D., and McCormick F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumour selectivity. Cancer Cell 6 (2004) 611-623
69. Partridge M., Emilion G., Pateromichelakis S., Phillips E., and Langdon J. Field cancerisation of the oral cavity: comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions. Eur J Cancer Oral Oncol 33 (1997) 332-337
70. Partridge M., Emilion G., Pateromichelakis S., A'Hern R., Phillips E., and Langdon J. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Eur J Cancer Oral Oncol 34 (1998) 77-83
71. Partridge M., Emilion G., Pateromichelakis S., A'Hern R., Lee G., Phillips E., and Langdon J. The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer. Br J Cancer 79 (1999) 1821-1827
72. Partridge M., Emilion G., Falworth M., A'Hern R., Phillips E., Pateromichelakis S., and Langdon J. Patient-specific mutation databases for oral cancer. Int J Cancer 84 (1999) 284-292
73. Partridge M., Kiguwa S., Emilion G., Pateromichelakis S., A'Hern R., and Langdon J.D. New insights into p53 protein stabilisation in oral squamous cell carcinoma. Eur J Cancer 35 (1999) 45-55
74. Partridge M., Li S.-R., Pateromichelakis S., Francis R.A., Phillips E., Huang X.-H., Tesfa-Selase F., and Langdon J.D. Detection of minimal residual cancer to investigate why oral tumours recur despite seemingly adequate treatment. Clin Cancer Res 6 (2000) 2718-2725
75. Partridge M., Pateromichelakis S., Phillips E., Emilion G.G., A'Hern R.P., and Langdon J.D. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral SCC within a field of cancerisation. Cancer Res 60 (2000) 3893-3898
76. Pateromichelakis S., Farahini M., Phillips E., and Partridge M. Molecular analysis of paired tumours: Time to start treating the field. Oral Oncol 41 (2005) 916-926
77. Partridge M., Gaballah K., and Huang X. Molecular markers for diagnosis and prognosis. Cancer Metast Rev 24 (2005) 71-85
78. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., Wilson J.M., and Batshaw M.L. Fatal systemic inflammatory response in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80 (2003) 148-158
79. Ratovitski E.A., Patturajan M., Hibi K., Trink B., Yamaguchi K., and Sidransky D. p53 associates with and targets Np63 into a protein degradation pathway. Proc Natl Acad Sci USA 98 (2001) 1817-1822
80. Reid T.R., Freeman S., Post L., McCormick F., and Sze D.Y. Effects of ONYX-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 12 (2005) 673-681
81. Rozemuller E.H., Kropveld A., Kreyveld E., Leppers F.G., and Scheidel K. Sensitive detection of p53 mutation: analysis by direct sequencing and multisequence analysis. Cancer Detect Prev 25 (2001) 109-116
82. Rocco J.W., Leong C.-O., Kuperwasser N., DeYoung M.P., and Ellison L.W. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9 (2006) 45-56
83. Rogulski K.R., Freytag S.O., Zhang K., Gilbert J.D., Paielli D.L., Kim J.H., Heise C.C., and Kirn D.H. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 60 (2000) 1193-1196
84. Rosin M.P., Cheng X., Poh C.F., Lam W.L., Huang Y., Lovas J., Berean K., Epstein J.B., Priddy R., Le N.D., and Zhang L. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 6 (2000) 357-362
85. Rudin C.M., Cohen E.E.W., and Papadimitrakopoulou V.A. An attenuated adenovirus ONYX-015 as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21 (2003) 4546-4552
86. Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Trigiante G., Hsieh J.K., Zhong S., Campargue I., Naumovski, Crook T., and Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8 (2001) 781-794
87. Schmale H., and Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene 15 (1997) 1363-1367
88. Sheikh M.S., Burns T.F., Huang Y., Wu G.S., Amundson S., Brooks K.S., Fornace A.J., and el-Deiry W.S. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 58 (1998) 1593-1598
89. Shin H.J., Kalapurakal S.K., Lee J.J., Ro J.Y., Hong W.K., and Lee J.S. Comparison of p53 immunoreactivity in fresh-cut versus stored slides with and without microwave heating. Mod Pathol 10 (1997) 224-230
90. Sniezek J.C., Matheny K.E., Westfall M.D., and Pietenpol J.A. Dominant Negative p63 Isoform Expression in Head and Neck Squamous Cell Carcinoma. Laryngoscope 114 (2004) 2063-2072
91. Soussi T., Asselain B., Hamroun D., Kato S., Ishioka C., Claustres M., and Beroud C. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 12 (2006) 62-69
92. Sullivan A., Syed N., Gasco M., Bergamaschi D., Trigiante G., Attard M., Hiller L., Farrell P.J., Smith P., Lu X., and Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23 (2004) 3328-3337
93. Townsend P.A., Scarabelli T.M., Davidson S.M., Knight R.A., Latchman D.S., and Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem 279 (2004) 5811-5820
94. van Houten V.M., Leemans C.R., Kummer J.A., Dijkstra J., Kuik D.J., van den Brekel M.W., Snow G.B., and Brakenhoff R.H. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res 10 (2004) 3614-3620
95. van Houten V.M., Snijders P.J., van den Brekel M.W., Kummer J.A., Meijer C.J., van Leeuwen B., Denkers F., Smeele L.E., Snow G.B., and Brakenhoff R.H. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 93 (2001) 232-235
96. Vasey P.A., Shulman L.N., Campos S., Davis J., Gore M., Johnston S., Kirn D.H., O'Neill V., Siddiqui N., Seiden M.V., and Kaye S.B. Phase I trial of intraperitoneal injection of the E1B-55-kD-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 20 (2002) 1562-1569
97. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., and Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
98. Waridel F., Estreicher A., Bron L., Flaman J.-M., Fontolliet C., Monnier P., Frebourg F., and Iggo R. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 14 (1997) 163-169
99. Wen W.H., Bernstein L., Lescallett J., Beazer-Barclay Y., Sullivan-Halley J., and White M. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res 60 (2000) 2716-2722
100. Wiest T., Schwarz E., Enders C., Flechtenmacher C., and Bosch F.X. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21 (2002) 1510-1517
101. Yamazaki Y., Chiba I., Hirai A., Sugiura C., Notani K., Kashiwazaki H., Tei K., Totsuka Y., and Fukuda H. Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma. Oral Oncol 39 (2003) 163-169
102. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., and McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2 (1998) 305-316
103. Zhu J.J., Jiang J., Zhou W., and Chen X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 58 (1998) 5061-5065